UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 20, 2016

ContraVir Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (732) 902-4000

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02              Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 20, 2016,  ContraVir Pharmaceuticals, Inc. (the “Company”) appointed Thomas Adams, Ph.D.. as a director of the Company, effective immediately.  Dr. Adams does not have any family relationship with any director, executive officer or person nominated or chosen by us to become a director or executive officer.  There is no understanding or arrangement between Dr. Adams and any other person pursuant to which Dr. Adams was selected as a director.  There are no transactions in which Dr. Adams has an interest requiring disclosure under Item 404(a) of Regulation S-K.  In connection with his appointment, Dr. Adams received an option to purchase 45,000 shares of the Company’s common stock exercisable at $1.12 per share, the closing price of the Company’s common stock on the Nasdaq Capital Market on September 19, 2016.  The options vest over three (3) years in 3 annual installments beginning on the one year anniversary of the date of issuance.

A copy of the press release announcing the appointment of Dr. Adams is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

Item 9.01.            Financial Statements and Exhibits.

(d)         Exhibits.

99.1   ContraVir Pharmaceuticals, Inc. Press Release dated September 21, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2